Inozyme Pharma (INZY) News Today $2.99 +0.18 (+6.41%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) PT at $17.00December 19 at 1:11 AM | americanbankingnews.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price target amoDecember 16, 2024 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Research Coverage Started at Raymond JamesDecember 15, 2024 | americanbankingnews.comInozyme initiated with an Outperform at Raymond JamesDecember 12, 2024 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Now Covered by Analysts at Raymond JamesRaymond James initiated coverage on shares of Inozyme Pharma in a report on Thursday. They issued an "outperform" rating and a $26.00 target price on the stock.December 12, 2024 | marketbeat.comEventide Asset Management LLC Raises Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)Eventide Asset Management LLC boosted its stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 5.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,134,436 shares of the company's sNovember 29, 2024 | marketbeat.comInozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Recommendation of "Buy" from BrokeragesShares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given an average rating of "Buy" by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month prNovember 21, 2024 | marketbeat.comInozyme Pharma to Present at Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comFY2024 EPS Estimates for Inozyme Pharma Raised by AnalystInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at HC Wainwright increased their FY2024 EPS estimates for Inozyme Pharma in a report issued on Wednesday, November 6th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.62) per share for the year, upNovember 8, 2024 | marketbeat.comFY2024 EPS Estimates for Inozyme Pharma Boosted by AnalystInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at Wedbush increased their FY2024 earnings estimates for shares of Inozyme Pharma in a report released on Tuesday, November 5th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($November 7, 2024 | marketbeat.comInozyme Pharma’s Q3 2024 Financial and Clinical ProgressNovember 6, 2024 | markets.businessinsider.comInozyme Pharma Receives Buy Rating for Promising Pipeline and Strategic AdvancementsNovember 6, 2024 | markets.businessinsider.comInozyme Pharma’s Strategic and Financial Positioning Bolsters Buy Rating Amid Upcoming Trial MilestonesNovember 6, 2024 | markets.businessinsider.comPromising Developments in Inozyme Pharma’s INZ-701 Drive Buy RecommendationNovember 6, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Inozyme Pharma (NASDAQ:INZY)Needham & Company LLC reissued a "buy" rating and set a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday.November 6, 2024 | marketbeat.comInozyme Pharma's (INZY) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of Inozyme Pharma in a research report on Wednesday.November 6, 2024 | marketbeat.comInozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 5, 2024 | globenewswire.comPiper Sandler Sticks to Its Buy Rating for Inozyme Pharma (INZY)October 29, 2024 | markets.businessinsider.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Buy" from AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price amongOctober 27, 2024 | marketbeat.comPromising Clinical Trial Results Justify Buy Rating for Inozyme PharmaOctober 26, 2024 | markets.businessinsider.comOptimistic Outlook on Inozyme Pharma’s INZ-701 Backed by Promising Trial Data and Market PotentialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday.October 25, 2024 | marketbeat.comInozyme announces ‘positive’ interim data from ongoing Phase 1 SEAPORT 1 trialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma Reports Promising Results in SEAPORT 1 TrialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma Bullish on Treatment for End-Stage Kidney DiseaseOctober 24, 2024 | marketwatch.comInozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701October 24, 2024 | globenewswire.comInozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | globenewswire.comInozyme Pharma, Inc. (NASDAQ:INZY) Short Interest UpdateInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 3,660,000 shares, a decrease of 6.9% from the September 15th total of 3,930,000 shares. Based on an average trading volume of 258,700 shares, the short-interest ratio is currently 14.1 days. Approximately 8.6% of the company's stock are sold short.October 16, 2024 | marketbeat.comDimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)Dimensional Fund Advisors LP raised its stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 117.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,064 shares of the company's stock after buying anOctober 12, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)Millennium Management LLC increased its position in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 154.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,787,947 shares of the company's stock after acquirOctober 10, 2024 | marketbeat.comInozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of DirectorsOctober 7, 2024 | globenewswire.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of "Buy" from BrokeragesShares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelveOctober 2, 2024 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from WedbushWedbush reissued an "outperform" rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Monday.September 30, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Shares Sold by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lessened its holdings in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 11.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,120,027 shares of the company's stock aSeptember 28, 2024 | marketbeat.comAffinity Asset Advisors LLC Acquires 213,733 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)Affinity Asset Advisors LLC increased its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 8.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,856,252 shares of the company's stock after acquiring an additionalSeptember 25, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Holdings Raised by Samlyn Capital LLCSamlyn Capital LLC grew its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 15.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,350,535 shares of the company's stock after purchaSeptember 24, 2024 | marketbeat.comStifel Initiates Coverage of Inozyme Pharma (INZY) with Buy RecommendationSeptember 13, 2024 | nasdaq.comInozyme draws buy at Stifel on lead assetSeptember 12, 2024 | msn.comInozyme Pharma (NASDAQ:INZY) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus initiated coverage on shares of Inozyme Pharma in a report on Thursday. They issued a "buy" rating and a $16.00 price objective on the stock.September 12, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by BrokeragesInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price amongSeptember 7, 2024 | marketbeat.comInozyme Pharma to Participate at the 2024 Wells Fargo Healthcare ConferenceAugust 29, 2024 | globenewswire.com3 Best Stocks to Buy Now, 8/13/2024, According to Top AnalystsAugust 14, 2024 | msn.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Rating of "Buy" by AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been given a consensus rating of "Buy" by the six analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updateAugust 13, 2024 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Given Buy Rating at Jefferies Financial GroupJefferies Financial Group reaffirmed a "buy" rating and issued a $17.00 price objective (up previously from $16.00) on shares of Inozyme Pharma in a research note on Tuesday.August 13, 2024 | marketbeat.comQ3 2024 EPS Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY) Lowered by HC WainwrightInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2024 earnings estimates for Inozyme Pharma in a report issued on Wednesday, August 7th. HC Wainwright analyst E. White now anticipates that the company will earn ($0.46) per share for the quarter,August 12, 2024 | marketbeat.comInstitutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term lossesAugust 12, 2024 | finance.yahoo.comInozyme Pharma, Inc. (NASDAQ:INZY) to Post Q3 2024 Earnings of ($0.45) Per Share, Wedbush ForecastsInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at Wedbush cut their Q3 2024 earnings per share (EPS) estimates for shares of Inozyme Pharma in a research report issued to clients and investors on Tuesday, August 6th. Wedbush analyst D. Nierengarten now forecasts that the comAugust 9, 2024 | marketbeat.comInozyme Pharma announces $23.8 million remaining in ATM programAugust 8, 2024 | uk.investing.comInozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Inozyme Pharma in a report on Thursday.August 8, 2024 | marketbeat.com Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW INZY Media Mentions By Week INZY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼0.340.60▲Average Medical News Sentiment INZY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼32▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Anavex Life Sciences News Immunome News Kura Oncology News Keros Therapeutics News Tyra Biosciences News Cronos Group News Erasca News Evolus News Rapport Therapeutics News Dianthus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
